Estrogen Receptor alpha Antibody Cocktail | Invitrogen MA5-14104 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

Estrogen Receptor alpha Antibody Cocktail

catalog :

MA5-14104

quantity :

500 uL

price :

US 656.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

1D5, 6F11

reactivity :

African green monkey, human, mouse, rat, chicken, cat, domestic rabbit, rhesus macaque

application :

western blot, immunohistochemistry, immunocytochemistry, EMSA, immunohistochemistry - paraffin section

more info or order :

Invitrogen product webpage

citations: 62

Published Application/Species/Sample/Dilution	Reference
western blot; human; 1:1000; fig s2e	Prekovic S, Schuurman K, Mayayo Peralta I, Manjón A, Buijs M, Yavuz S, et al. Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. Nat Commun. 2021;12:4360 pubmed publisher
immunohistochemistry; human; 1:200	Khandakar B, Mathur S, Kumar L, Kumar S, Datta Gupta S, Iyer V, et al. Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. Biomed Res Int. 2014;2014:401245 pubmed publisher
western blot; human	Lee J, Tiwari A, Shum V, Mills G, Mancini M, Igoshin O, et al. Unraveling the regulatory connections between two controllers of breast cancer cell fate. Nucleic Acids Res. 2014;42:6839-49 pubmed publisher
immunohistochemistry; human; 1:100	Bredow L, Stützel L, Böhringer D, Gundlach E, Reinhard T, Auw Haedrich C. Progesterone and estrogen receptors in conjunctival melanoma and nevi. Graefes Arch Clin Exp Ophthalmol. 2014;252:359-65 pubmed publisher
EMSA; human	Kruer T, Cummins T, Powell D, Wittliff J. Characterization of estrogen response element binding proteins as biomarkers of breast cancer behavior. Clin Biochem. 2013;46:1739-46 pubmed publisher
immunohistochemistry; human; 1:50	Grosso S, Katayama M, Roela R, Nonogaki S, Soares F, Brentani H, et al. Breast cancer tissue slices as a model for evaluation of response to rapamycin. Cell Tissue Res. 2013;352:671-84 pubmed publisher
western blot; human	Endoh T, Kawasaki Y, Sugimoto N. Stability of RNA quadruplex in open reading frame determines proteolysis of human estrogen receptor ?. Nucleic Acids Res. 2013;41:6222-31 pubmed publisher
immunohistochemistry; human western blot; human	Li Y, Meeran S, Patel S, Chen H, Hardy T, Tollefsbol T. Epigenetic reactivation of estrogen receptor-Î± (ERÎ±) by genistein enhances hormonal therapy sensitivity in ERÎ±-negative breast cancer. Mol Cancer. 2013;12:9 pubmed publisher
immunohistochemistry; human; 1:500	Laliotis A, Vrekoussis T, Kafousi M, Sanidas E, Askoxilakis J, Melissas J, et al. Immunohistochemical study of pElk-1 expression in human breast cancer: association with breast cancer biologic profile and clinicopathologic features. Breast. 2013;22:89-95 pubmed publisher
immunocytochemistry; human; 1:35	Marinšek Z, Nolde N, Kardum Skelin I, Nizzoli R, Onal B, Rezanko T, et al. Multinational study of oestrogen and progesterone receptor immunocytochemistry on breast carcinoma fine needle aspirates. Cytopathology. 2013;24:7-20 pubmed publisher
immunohistochemistry; human; 1:100	Marian C, Boilă A, Soanca D, Malau M, Podeanu D, Resetkova E, et al. Malignant transformation of adenomyoepithelioma of the breast by a monophasic population: a report of two cases and review of literature. APMIS. 2013;121:272-9 pubmed publisher
immunohistochemistry; human	Gill M, Paish E, Ronan J, Green A, Ellis I, Lee A. Comparison of the PharmDx immunohistochemical system with standard methods for assessing estrogen and progesterone receptors in invasive carcinoma of the breast. Appl Immunohistochem Mol Morphol. 2013;21:90-3 pubmed publisher
immunohistochemistry; chicken; 1:200	Machado S, Bahr J, Hales D, Braundmeier A, Quade B, Nowak R. Validation of the aging hen (Gallus gallus domesticus) as an animal model for uterine leiomyomas. Biol Reprod. 2012;87:86 pubmed publisher
immunohistochemistry; human; 1:50	Martins F, De S, Almendro V, Gonen M, Park S, Blum J, et al. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov. 2012;2:503-11 pubmed publisher
immunohistochemistry; rhesus macaque	Almeida Francia C, Keator C, Mah K, Holden L, Hergert C, Slayden O. Localization and hormonal regulation of endometrial matrix metalloproteinase-26 in the rhesus macaque. Hum Reprod. 2012;27:1723-34 pubmed publisher
immunohistochemistry; human; 1:100	Hovanessian Larsen L, Taylor D, Hawes D, Spicer D, Press M, Wu A, et al. Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial. Contraception. 2012;86:238-43 pubmed publisher
immunohistochemistry; human	Maae E, Olsen D, Steffensen K, Jakobsen E, Brandslund I, Sørensen F, et al. Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res Treat. 2012;133:257-65 pubmed publisher
immunohistochemistry; human; 1:100	Chung K, Hovanessian Larsen L, Hawes D, Taylor D, Downey S, Spicer D, et al. Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation. Breast Cancer Res Treat. 2012;132:653-60 pubmed publisher
immunohistochemistry; human; 1:50	Rijlaarsdam M, van Herk H, Gillis A, Stoop H, Jenster G, Martens J, et al. Specific detection of OCT3/4 isoform A/B/B1 expression in solid (germ cell) tumours and cell lines: confirmation of OCT3/4 specificity for germ cell tumours. Br J Cancer. 2011;105:854-63 pubmed publisher
immunohistochemistry; human; 1:50	Logullo A, Stiepcich M, Osório C, Nonogaki S, Pasini F, Rocha R, et al. Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma. Histopathology. 2011;58:617-25 pubmed publisher
immunohistochemistry; human; 1:100	Gschwantler Kaulich D, Fink Retter A, Czerwenka K, Hudelist G, Kaulich A, Kubista E, et al. Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases. Tumour Biol. 2011;32:501-8 pubmed publisher
immunohistochemistry; human; 1:50	Joosse S, Brandwijk K, Mulder L, Wesseling J, Hannemann J, Nederlof P. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosomes Cancer. 2011;50:71-81 pubmed publisher
immunohistochemistry; human; 1:50	Holstege H, van Beers E, Velds A, Liu X, Joosse S, Klarenbeek S, et al. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers. BMC Cancer. 2010;10:455 pubmed publisher
immunohistochemistry; human; 1:50	Joosse S, Brandwijk K, Devilee P, Wesseling J, Hogervorst F, Verhoef S, et al. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. Breast Cancer Res Treat. 2012;132:379-89 pubmed publisher
immunohistochemistry; human; 1:100	Horlings H, Lai C, Nuyten D, Halfwerk H, Kristel P, van Beers E, et al. Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients. Clin Cancer Res. 2010;16:651-63 pubmed publisher
immunohistochemistry; human; 1:200	Bueno de Mesquita J, Nuyten D, Wesseling J, VAN Tinteren H, Linn S, van de Vijver M. The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol. 2010;21:40-7 pubmed publisher
immunohistochemistry; cat	Misirlioglu D, Nak D, Ozyigit M, Nak Y, Akkoc A. HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats. J Feline Med Surg. 2009;11:885-8 pubmed publisher
immunohistochemistry; human; 1:50	Pietersen A, Horlings H, Hauptmann M, Langerød A, Ajouaou A, Cornelissen Steijger P, et al. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res. 2008;10:R109 pubmed publisher
immunohistochemistry; human; 1:100	Ceausu M, Terzea D, Georgescu A, Dobrea C, Mihai M, Iosif C, et al. Transitional cell tumors of the ovary: a compact group with a heterogeneous histological and immunophenotypical pattern. Rom J Morphol Embryol. 2008;49:513-6 pubmed
immunohistochemistry; human; 1:100	Chakravarty D, Srinivasan R, Ghosh S, Rajwanshi A, Gopalan S. Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma. Appl Immunohistochem Mol Morphol. 2008;16:535-42 pubmed publisher
immunohistochemistry; human; 1:50	Joosse S, van Beers E, Tielen I, Horlings H, Peterse J, Hoogerbrugge N, et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat. 2009;116:479-89 pubmed publisher
immunohistochemistry; human; 1:100	Bao H, Yu D, Wang J, Qiu T, Yang J, Wang L. Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherap. Anticancer Drugs. 2008;19:317-23 pubmed
immunohistochemistry; human	Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res. 2007;13:6064-9 pubmed
immunohistochemistry; human; 1:50	Berns K, Horlings H, Hennessy B, Madiredjo M, Hijmans E, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395-402 pubmed
immunohistochemistry; domestic rabbit; 1:50	Onal B, Levin R, Kogan B, Whitbeck C, Chichester P, Walebowa O, et al. The effect of maturation and age on oestrogen-induced functional hypertrophy of the female rabbit bladder. BJU Int. 2007;99:674-9 pubmed
immunohistochemistry; human; 1:100	Singer C, Fink Retter A, Gschwantler Kaulich D, Thalhammer T, Hudelist G, Mueller R, et al. Selective spatial upregulation of intratumoral stromal aromatase in breast cancer patients: evidence for imbalance of local estrogen metabolism. Endocr Relat Cancer. 2006;13:1101-7 pubmed
immunohistochemistry; human	Schmidt M, Tollenaar R, de Kemp S, Broeks A, Cornelisse C, Smit V, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 2007;25:64-9 pubmed
immunohistochemistry; human; 1:50	Hannemann J, Kristel P, VAN Tinteren H, Bontenbal M, van Hoesel Q, Smit W, et al. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer. 2006;95:1334-41 pubmed
immunohistochemistry; human	Wang M, Pan J, Song G, Chen H, An L, Qu S. Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters. Eur J Surg Oncol. 2007;33:195-201 pubmed
immunohistochemistry; human; 4 ug/ml immunohistochemistry; chicken	Berry W, Doernte A, Conner M, Barnes M, Oates S. Spontaneously occurring fibroid tumors of the laying hen oviduct. Poult Sci. 2006;85:1969-74 pubmed
immunohistochemistry; domestic rabbit	Lin A, Levin R, Kogan B, Whitbeck C, Chichester P, Sokol R, et al. Estrogen induced functional hypertrophy and increased force generation of the female rabbit bladder. Neurourol Urodyn. 2006;25:473-9 pubmed
western blot; human; 1:100	Turbyville T, Wijeratne E, Liu M, Burns A, Seliga C, Luevano L, et al. Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert. J Nat Prod. 2006;69:178-84 pubmed
immunohistochemistry; mouse; 1:50	Wang R, Zhang H, Balasenthil S, Medina D, Kumar R. PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene. 2006;25:2931-6 pubmed
immunohistochemistry; rat western blot; rat	Weroha S, Li S, Tawfik O, Li J. Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats. Carcinogenesis. 2006;27:491-8 pubmed
western blot; human; 1:750 immunocytochemistry; African green monkey; 1:200	Lipfert L, Fisher J, Wei N, Scafonas A, Su Q, Yudkovitz J, et al. Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation. Mol Endocrinol. 2006;20:516-33 pubmed
immunohistochemistry; human; 1:100	Gao R, Bao H, Yang Q, Cong Q, Song J, Wang L. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Breast Cancer Res Treat. 2005;93:111-5 pubmed
immunohistochemistry; human	Inceboz U, Nese N, Uyar Y, Ozcakir H, Kurtul O, Baytur Y, et al. Hormone receptor expressions and proliferation markers in postmenopausal endometrial polyps. Gynecol Obstet Invest. 2006;61:24-8 pubmed
immunohistochemistry; human; 1:100	Akhan S, Yavuz E, Tecer A, Iyibozkurt C, Topuz S, Tuzlali S, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol. 2005;99:36-42 pubmed
immunohistochemistry; rat	Qiu C, Shan L, Yu M, Snyderwine E. Steroid hormone receptor expression and proliferation in rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Carcinogenesis. 2005;26:763-9 pubmed
	Mayayo Peralta I, Faggion B, Hoekman L, Morris B, Lieftink C, Goldsbrough I, et al. Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer. Cancers (Basel). 2021;13: pubmed publisher
	He W, Demas D, Conde I, Shajahan Haq A, Baumann W. Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition. J R Soc Interface. 2020;17:20200339 pubmed publisher
	Flötotto T, Niederacher D, Hohmann D, Heimerzheim T, Dall P, Djahansouzi S, et al. Molecular mechanism of estrogen receptor (ER)alpha-specific, estradiol-dependent expression of the progesterone receptor (PR) B-isoform. J Steroid Biochem Mol Biol. 2004;88:131-42 pubmed
	Guler G, Uner A, Guler N, Han S, Iliopoulos D, Hauck W, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer. 2004;100:1605-14 pubmed
	Kapucuoglu N, Coban T, Raunio H, Pelkonen O, Edwards R, Boobis A, et al. Expression of CYP3A4 in human breast tumour and non-tumour tissues. Cancer Lett. 2003;202:17-23 pubmed
	Beliakoff J, Bagatell R, Paine Murrieta G, Taylor C, Lykkesfeldt A, Whitesell L. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res. 2003;9:4961-71 pubmed
	Bethea C, Lu N, Reddy A, Shlaes T, Streicher J, Whittemore S. Characterization of reproductive steroid receptors and response to estrogen in a rat serotonergic cell line. J Neurosci Methods. 2003;127:31-41 pubmed
	Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer C. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat. 2003;78:193-204 pubmed
	Zinser G, McEleney K, Welsh J. Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice. Mol Cell Endocrinol. 2003;200:67-80 pubmed
	Seth P, Porter D, Lahti Domenici J, Geng Y, Richardson A, Polyak K. Cellular and molecular targets of estrogen in normal human breast tissue. Cancer Res. 2002;62:4540-4 pubmed
	Querzoli P, Albonico G, di Iasio M, Ferretti S, Rinaldi R, Cariello A, et al. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women. Breast Cancer Res Treat. 2001;66:135-42 pubmed
	Suzuki T, Darnel A, Akahira J, Ariga N, Ogawa S, Kaneko C, et al. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. J Clin Endocrinol Metab. 2001;86:2250-7 pubmed
	El Khissiin A, Journe F, Laios I, Seo H, Leclercq G. Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells. Steroids. 2000;65:903-13 pubmed

product information

Product Type :

Antibody

Product Name :

Estrogen Receptor alpha Antibody Cocktail

Catalog # :

MA5-14104

Quantity :

500 uL

Price :

US 656.00

Clonality :

Cocktail

Host :

Mouse

Reactivity :

Human

Applications :

Immunocytochemistry: 1:50-1:200, Immunohistochemistry (Paraffin): 1:50-1:100, Western Blot: 1:50-1:100

Species :

Human

Clone :

1D5, 6F11

Isotype :

IgG1

Storage :

4 C

Description :

Estrogen Receptors (ER) are members of the steroid/thyroid hormone receptor superfamily of nuclear receptors. The estrogen receptor is a ligand-activated transcription factor, that when bound to estrogen hormone, induces a conformational change that allows dimerization and binding to estrogen response elements (ERE) in DNA. When bound to EREs, ER can positively or negatively regulate gene transcription through the recruitment of coactivator or corepressor proteins. There are two different forms of the estrogen receptor, alpha and beta, encoded by separate genes (ESR1 and ESR2, respectively). Due to alternative RNA splicing, at least 4 estrogen receptor-alpha isoforms are known to exist (Isoform 1 (66 kDa), Isoform 2 (53 kDa), Isoform 3 (47 kDa), Isoform 4 (35 kDa)). Estrogen receptors are widely expressed in different tissue types and are essential for sexual development and reproductive function. They also play a role in other tissues such as bone. Estrogen receptors are involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis.

Immunogen :

Recombinant human estrogen receptor protein

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1:50-1:200, Immunohistochemistry (Paraffin): 1:50-1:100, Western Blot: 1:50-1:100

Aliases :

DKFZp686N23123; ER; Er alpha; ER36; ERa; ERalpha; ER-alpha; ERalpha protein; ESR; esr 1; Esr1; esr-1; ESRA; Estr; Estra; Estradiol receptor; estrogen nuclear receptor alpha; Estrogen receptor; estrogen receptor 1; estrogen receptor 1 (alpha); estrogen receptor alpha; estrogen receptor alpha c-terminus splice variant 1-2; estrogen receptor alpha E1-E2-1-2; estrogen receptor alpha E1-N2-E2-1-2; estrogen receptor alpha splice variant, CTERP-1; estrogen receptor alpha splice variant, ERalphaDup5; estrogen receptor alpha splice variant, ERalphai45a; estrogen receptor alpha splice variant, ERalphai45bL; estrogen receptor alpha splice variant, ERalphai45bS; estrogen receptor alpha splice variant, ERalphai45c; estrogen receptor alpha splice variant, ERalphai56; estrogen receptor alpha splice variant, ERalphai67; estrogen receptor alpha variant delta 4; estrogen receptor protein; estrogen receptor, alpha; ESTRR; hER-alpha36; I79_001166; Nr3a1; nuclear receptor; nuclear receptor subfamily 3 group A member 1; RNESTROR; RP1-130E4.1; unnamed protein product

more info or order :

Invitrogen product webpage